key: cord-0701701-5tpo1dw8
authors: Stokes, W.; Venner, A.; Buss, E.; Tipples, G.; Berenger, B.
title: Then and NOW: A Prospective Population-Level Validation of the Abbott ID NOW SARS-CoV-2 Device Implemented in Multiple Settings for Testing Asymptomatic and Symptomatic Individuals
date: 2022-05-02
journal: nan
DOI: 10.1101/2022.04.30.22274189
sha: 22b7e20d892d46a01bdb4517903b26b2261dcb73
doc_id: 701701
cord_uid: 5tpo1dw8

INTRODUCTION Since December, 2020, the ID NOW was implemented for use in 4 different populations across Alberta: in mobile units as part of community outbreak response, COVID19 community collection sites, emergency shelters and addiction treatment facilities (ES), and hospitals. OBJECTIVE Diagnostic evaluation of the ID NOW in various real world settings among symptomatic and asymptomatic individuals METHODS Depending on the implemented site, the ID NOW was tested on patients with symptoms suggestive of COVID-19, asymptomatic close contacts or asymptomatic individuals as part of outbreak point prevalence screening. From Jan to April, a select number of sites also switched from using oropharyngeal swabs to combined oropharyngeal + nasal (O+N) swabs. For every individual tested, two swabs were collected: one for ID NOW testing and the other for either reverse-transcriptase polymerase chain reaction (RTPCR) confirmation of negative ID NOW results or for variant testing of positive ID NOW results. RESULTS A total of 129,112 paired samples were analyzed (16,061 RTPCR positive). 81,697 samples were from 42 COVID-19 community collection sites, 16,924 from 69 rural hospitals, 1,927 from 9 ES, 23,802 samples from 6 mobile units that responded to 356 community outbreaks, and 4,762 from 3 community collection sites and 1 ES using O+N swabs for ID NOW testing. ID NOW sensitivity was highest among symptomatic individuals presenting to community collection sites [92.5%, 95% confidence interval (CI) 92.0-93.0%, n=10,633 RTPCR positive] and lowest for asymptomatic individuals associated with community outbreaks (73.9%, 95% CI 69.8 to 77.7%, n=494 RTPCR positive). Specificity was greater than 99% in all populations tested, but positive predictive value (PPV) was lower among asymptomatic populations (82.4 to 91.3%) compared to symptomatic populations (96.0 to 96.9%). There was no statistically significant differences in sensitivity with respect to age, gender, NP vs OP swab for RTPCR confirmation, variants of concern, or with combined oropharyngeal and nasal swabs using COVID-19 ID NOW testing. CONCLUSIONS Sensitivity of ID NOW SARS CoV2 testing is highest when used on symptomatic community populations not seeking medical care. Sensitivity and PPV drops by approximately 10% when tested on asymptomatic populations. Using combined oropharyngeal and nasal swabs did not improve ID NOW performance.

Individuals were given the option to have POCT by ID NOW and routine testing, or routine 132 testing alone. All individuals tested with the ID NOW had two parallel swabs collected. The first 133 swab collected was either a NP swab or oropharyngeal (OP) swab, which was placed in UTM 134 (Yocon Biology, Beijing, China or GDL Korea Co. Ltd, Seoul, Korea) for RT-PCR, and 135 transported to an accredited laboratory at room temperature and stored at 4 o C until processing. 136

The second swab was an OP swab for ID NOW testing (using the OP swab provided in the ID 137 NOW kits). The OP swab for ID NOW testing was always collected second to ensure all 138 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (HCW), who were previously trained in NP and oropharyngeal swab collection. At time of 159 collection, they asked and recorded whether the patient had symptoms or was asymptomatic. All 160 sites and HCW were trained on the ID NOW collection, transport, and testing processes, at least 161 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ID NOW device underwent a verification process, which included testing 3 positive ID NOW  164 control swabs and 5 negative ID NOW control swabs on the ID NOW instrument before use. 165

One positive control and one negative control swab were tested on the ID NOW instrument after 166 each new box of ID NOW kits was opened, after each new HCW was trained on the instrument, 167 and, after each instrument was transported to a different site. Sensitivity and specificity of the ID NOW was calculated with Clopper-Pearson 95% confidence 182 intervals. Statistical analysis was performed using Pearson Chi-squared for categorical variables 183 and t-test for continuous variables using STATA (version 14.1). 184 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. from 9 shelters and addiction treatment facilities, and 23,802 samples were from 6 mobile units 197 that responded to 356 outbreaks. Baseline characteristics of these samples is provided in Table 1 . 198 Results, compared to RT-PCR, are provided in Table 2 Positive predictive value (PPV) was highest for symptomatic individuals presenting to 206 assessment centres (PPV 96.9%, 95% CI 96.5-97.2%), followed by symptomatic patients in 207 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 . There was no statistically significant differences in sensitivity or 243 specificity noted between results from ID NOW using oropharyngeal swabs and those using 244 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.30.22274189 doi: medRxiv preprint ID NOW sensitivity was slightly lower in the symptomatic populations tested using a mobile 277 service or in-hospital based settings. There may be various factors to account for this. Firstly, ID 278 NOW testing is performed immediately after sample collection at assessment centres, whereas 279 hospitals and mobile service often require transportation to the on-site lab or mobile unit prior to 280 ID NOW testing. While ID NOW testing was mandated to be done within 1 hour from 281 collection, short periods of time from transportation may potentially affect performance. in sensitivity compared to other testing methods (RT-PCR). However, the sensitivity of the ID 298 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Strengths of this study include the large sample size and including both symptomatic and 328 asymptomatic populations. We also studied testing in various real world locations, including 329 community COVID-19 assessment centres, hospitals (inpatient and ED), emergency shelters and 330 addiction treatment facilities, and continuing care and industry outbreaks. Due to the introduction 331 of mandatory testing of many positive ID NOW or RT-PCR samples for variants of concern, 332 which included E gene RT-PCR from a consistent RT-PCR testing platform (APL LDT), we 333 were able to assess the specificity of the ID NOW and examine the relationship of E gene Ct 334 values between true positive and false negative ID NOW results. 335 336 Our study had several limitations. Due to the heterogeneity of our populations tested, it is 337 difficult to exclude confounders that may have contributed to ID NOW performance. However, 338 no differences were observed in sensitivity based on common patient, collecting and testing 339 characteristics, including age, gender, swab used, and variants of concern detected. Specificity 340 was increased for RT-PCR samples collected using oropharyngeal swabs, but this difference was 341 slight and limited to symptomatic populations. Exclusion of some ID NOW positive results from 342 our study because of no parallel RT-PCR testing did have an impact on ID NOW performance, 343 as evidenced by improved sensitivity (93.5% vs 92.5%), among symptomatic community 344 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.30.22274189 doi: medRxiv preprint patients presenting to assessment centres, when including these positive samples. Reasons 345 behind missing parallel RT-PCR are multifactorial and include sample lost or discarded prior to 346 testing, testing sites going against guidelines and not obtaining a second swab for RT-PCR 347 confirmation, and patient demographic mismatches resulting in test cancellation or inability to 348 match ID NOW and RT-PCR tests together in our electronic database. These excluded samples, 349 however, would have little impact on ID NOW sensitivity and specificity outside of symptomatic 350 individuals presenting to assessment centres. For instance, no significant changes in sensitivity 351 among asymptomatic community patients that presented to assessment centres were observed 352 when the 1822 excluded positive results were subsequently analyzed. 353

In conclusion, the performance of the ID NOW differs across populations tested for SARS-CoV-355 2. ID NOW performance can be maximized if testing is limited to symptomatic individuals 356 presenting to community testing sites (assessment centres). Sensitivity drops by approximately 357 10% when the testing population is asymptomatic. ID NOW performance is not affected by age, 358 gender, or variants of concern (alpha, delta). ID NOW testing with combined oropharyngeal + 359 nasal swab had no effect on performance. 360 361 362

This work was funded using internal operating funds of Alberta Precision Laboratories and 364 Alberta Health Services. Test kits and instruments were paid for by the Public Health Agency of 365 Canada. We thank staff at AHS assessment centre, mobile teams, and staff at shelters and 366 addiction recovery sites for collecting and testing samples in the community, and Alberta 367 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.30.22274189 doi: medRxiv preprint

United States Food and Drug Administration

Direct comparison of SARS-CoV-2 analytical limits of detection across seven 384 molecular assays

Comparative study of four SARS-CoV-2

Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW 387 performance is impaired substantially by patient and specimen type

Rapid, point-of-care antigen and molecular-based 390 tests for diagnosis of SARS-CoV-2 infection

Wide variation in threshold cycle 393 values clouds the interpretation of SARS-CoV-2 infectiousness

Combined throat/nasal swab 396 sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling

Combined oropharyngeal/nasal swab is equivalent to 399 nasopharyngeal sampling for SARS-CoV-2 diagnostic PCR

Performance of saliva, 402 oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a 403 systematic review and meta-analysis

9-38.4) 31.8 (33.2, 18.5-40.-type (35.6%) Delta (35.6%) Alpha (10.2%) Unresolved (16.9%) Other** (0.5%) 25.9 (26.2

Asymptomatic Wild-type (17.6%) Delta (20.3%) Alpha (26.5%) Unresolved (32.7%) Other** (2.9%)

COMBINED OROPHARYNGEAL AND NASAL (O+N) SWAB Assessment centre Symptomatic Wild-type (59.3%) Alpha (28.4%) Unresolved (12.1%)

Gamma, non-variant of concern, Unknown)

01 for all comparisons of mean E gene Ct of true positives vs false negatives and symptomatic vs asymptomatic within each group, with the 471 exception of false negatives between symptomatic vs asymptomatic in mobile testing and in assessment centres using O+N swabs

All rights reserved. No reuse allowed without permission

which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity